$5.55M Metformin NDMA Contamination Class Action Settlement
We don't collect claim information or sell leads to law firms. This site is paid for by ads.
A $5.55 million class action settlement resolves allegations that certain metformin-containing drugs were contaminated with NDMA (N-Nitrosodimethylamine). If you paid for qualifying metformin medications during the eligible period, you may be entitled to a cash payment — with no proof of purchase required.
Do I Qualify?
You may be eligible if:
- You are in the United States
- You paid for a qualifying metformin-containing drug between July 20, 2015 and June 2, 2020
- You submit a valid claim by July 21, 2026
No proof is required. You do not need to provide proof of purchase to file a claim.
This settlement closed on July 21, 2026 — see open settlements like this.
Browse open settlements →What Happened?
Several pharmaceutical companies — including Teva Pharmaceuticals, Granules India, and Heritage Pharmaceuticals — were sued after it was discovered that their generic metformin diabetes medications were contaminated with N-Nitrosodimethylamine (NDMA), a probable human carcinogen. The FDA issued recalls of contaminated metformin products in 2020.
Patients who had purchased and taken these contaminated medications were potentially exposed to elevated cancer risk without their knowledge. The companies agreed to pay a combined $5.55 million to settle the class action brought by affected patients.
How Much Will I Actually Get?
No proof of purchase is required — you simply confirm you purchased a qualifying metformin-containing medication between July 20, 2015 and June 2, 2020. The settlement fund of $5.55 million divided among eligible claimants means individual payments will depend on the number of valid claims. Deadline is July 21, 2026.
Last reviewed: June 19, 2026 | Information verified from court records and official settlement documents.
Frequently Asked Questions
Who qualifies for the metformin NDMA settlement?
New settlements, once a week. Deadlines only — no filler.